1OP 2198

Drug Profile

1OP 2198

Alternative Names: 1OP 2198; VRX 621698; XEN1101

Latest Information Update: 04 May 2017

Price : $50

At a glance

  • Originator Unknown
  • Developer 1st Order Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action KCNQ potassium channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Neurological disorders

Most Recent Events

  • 26 Apr 2017 Xenon Pharmaceuticals announces intention to submit IND for Seizures
  • 26 Apr 2017 Xenon Pharmaceuticals acquires XEN 1101 from 1st Order Pharmaceuticals
  • 26 Apr 2017 Xenon Pharmaceuticals plans a phase I trial for Seizures in the fourth quarter of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top